Europe Cold Chain Biologic Temperature Monitoring Labels Market Size & Outlook, 2026-2034
Europe Cold Chain Biologic Temperature Monitoring Labels Market Insights
- As highlighted in Packaging Market Insights analysis, the Europe Cold Chain Biologic Temperature Monitoring Labels Market, valued at USD 0.18 Billion in 2025, is estimated to achieve USD 0.45 Billion by 2034.
- The market is estimated to grow at a CAGR of 10.54% spanning 2026 to 2034.
- By market size, Irreversible Temperature Monitoring Labels led the Type category in 2025.
- The Type segment led by Irreversible Temperature Monitoring Labels is estimated to post the fastest growth, sustaining its position as the most lucrative during the forecast timeframe.
Source: PIAnalysis Company Publications, Primary Interviews.
Other Key Findings
- In 2025, Europe accounted for 24.32% of the global Cold Chain Biologic Temperature Monitoring Labels Market size.
- By 2034, United States is projected to lead the global market in terms of market size.
- Nordic is projected to emerge as the fastest-growing market in Europe, reaching USD 0.03 Billion by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 0.18 Billion |
| Market Size In 2034 | USD 0.45 Billion |
| Largest segment | Irreversible Temperature Monitoring Labels |
| Units | Revenue in USD Billion |
| CAGR | 10.54% (2026-2034) |
| Segmnetation Covered | |
| Europe |
|
| Type |
|
| Application |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Europe Cold Chain Biologic Temperature Monitoring Labels Market Country 2026-2034 (USD Billion)
| Europe | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Germany | XX.x | XX.x | XX.x | 0.04 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| United Kingdom | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| France | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Italy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Spain | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Russia | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Nordic | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Benelux | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: PIAnalysis Company Publications, Primary Interviews.
Europe Cold Chain Biologic Temperature Monitoring Labels Market Type 2026-2034 (USD Billion)
| Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Irreversible Temperature Monitoring Labels | XX.x | XX.x | XX.x | 0.08 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Reversible Temperature Monitoring Labels | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Digital Temperature Monitoring Labels | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: PIAnalysis Company Publications, Primary Interviews.
Europe Cold Chain Biologic Temperature Monitoring Labels Market Application 2026-2034 (USD Billion)
| Application | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmaceutical & Biopharmaceutical Logistics | XX.x | XX.x | XX.x | 0.08 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Vaccine Distribution | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Clinical Trials & Research | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: PIAnalysis Company Publications, Primary Interviews.